Navigation Links
Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
Date:5/30/2008

opment include two TRAIL receptor antibodies and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins for the treatment of cancer. In addition, HGS has substantial financial rights to three products in the GlaxoSmithKline clinical development pipeline.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Calif. , May 21, 2013 ... and manufacture of wireless personal healthcare products and ... its reach, announcing the release of two new ... blood pressure monitors and scales: the Wireless Pulse ... (Photo: http://photos.prnewswire.com/prnh/20130521/SF17618 ) ...
(Date:5/21/2013)... May 21, 2013 BioElectronics Corp. (PINKSHEETS: ... electronic devices, announced that CEO, Andrew ... the FDA,s Medical Advisory Committee, Orthopedic and Rehabilitation ... for over the counter sales. "It,s ... medical device classification schema," Whelan said.  "While the ...
(Date:5/21/2013)... and TARRYTOWN, N.Y. , ... NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today ... published online the positive Phase 2a study results ...  Dupilumab is an investigational monoclonal antibody targeting the alpha ... modulates signaling of both IL-4 and IL-13, drivers of ...
Breaking Medicine Technology:iHealth Lab adds new products and partners to mobile personal healthcare offering 2iHealth Lab adds new products and partners to mobile personal healthcare offering 3BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7
... , Feb. 16 CalciMedica today announced that the ... No. 7,645,588, a composition patent involving STIM1, a key component of ... a cell comprising a STIM1 protein and an agent that modulates ... March 4, 2003 and was issued on January ...
... LAWRENCEVILLE, N.J. , Feb. 16 ... today that Wayne S. Mulcahy , Ph.D., has ... wholly owned subsidiary of Princeton Pharma Holdings LLC, Aton ... products in ophthalmology and orphan diseases. , The ...
Cached Medicine Technology:CalciMedica Announces Issuance of US Patent No. 7,645,588, a Composition Patent Involving STIM1, a Key Component of the CRAC Channel 2Aton Pharma Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations 2
(Date:5/21/2013)... (PRWEB) May 21, 2013 Arizona ... inventors who want to develop their ideas into ... program. , The university is recruiting participants ... new “formation space” that provides early-stage entrepreneurs with ... AREA48 is open to anyone, ASU is particularly ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve ... the Creative Corridor region, is releasing results for its ... on Thursday, May 23rd at 10:30 a.m. The ... , The survey is a critical component to ... attract, nurture and retain people of diverse backgrounds, cultures ...
(Date:5/21/2013)... Boston, Mass.By studying the roles two proteins, thrombospondin-1 ... trans-Atlantic research team has identified a five-amino acid ... in mouse models of prostate, breast and lung ... could potentially block metastasis in a variety of ... Randolph Watnick, PhD, at Boston Children,s Hospital, Vivek ...
(Date:5/21/2013)... 2013 The nation’s first trial involving ... nearing its conclusion in Washington state court, Bernstein Liebhard ... yesterday, an attorney for the Plaintiffs compared Intuitive Surgical ... tie sales and services for its customers. ... control of surgeons, to keep control of hospitals and ...
(Date:5/21/2013)... A new study appearing in the current ... cells harvested from fat (adipose) are more potent than ... the body’s immune system. , The finding could ... adipose tissue-derived stem cells (AT-SCs) are far more plentiful ... and can be collected from waste material from liposuction ...
Breaking Medicine News(10 mins):Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3
... simple as developing a taste for yerba mate tea? In ... colon cancer cells die when they are exposed to the ... this brew, which has long been consumed in South America ... tea not only induced death in human colon cancer cells, ...
... of Nebraska-Lincoln will lead a $25 million project to reduce ... coli strains that pose a major threat to public ... Food and Agriculture announced the grant at UNL on Monday, ... coli , or STEC, which cause more than 265,000 illnesses ...
... professor is turning to nutrition to tackle prostate cancer. ... make more informed diet decisions by studying foods and dietary ... cancer is one of the most common forms of cancer ... researching ways to prevent prostate cancer rather than how to ...
... discovered 13 new regions of the genome associated with the ... pathways involved in reproductive lifespan and will provide insights into ... disease. Menopause is a major hormonal change ... 50s. The timing of menopause can have a huge impact ...
... FRIDAY, Jan. 20 (HealthDay News) -- The number of people ... of the disorder is adopted by mental health experts later ... the changes will be, but they agree there will be ... the professionals who treat them. The changes could affect the ...
... patients treated for breast cancer is seriously compromised and ... menopause, a decrease in physical activity and weight gain, ... Comprehensive Cancer Center. , The study, published in the ... found that the mental issues faced by younger breast ...
Cached Medicine News:Health News:Compounds in mate tea induce death in colon cancer cells 2Health News:U. of Nebraska to lead $25 million project targeting E. coli threat 2Health News:U. of Nebraska to lead $25 million project targeting E. coli threat 3Health News:Eating smart: Researcher studies foods, dietary supplements that may reduce risk of prostate cancer 2Health News:Genes and timing of menopause 2Health News:Experts Weigh Changes to Definition of Autism 2Health News:Experts Weigh Changes to Definition of Autism 3Health News:Quality of life for younger breast cancer patients more adversely affected than older women 2Health News:Quality of life for younger breast cancer patients more adversely affected than older women 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: